The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia
Article first published online: 14 APR 2010
Copyright © 2010 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry
Volume 26, Issue 1, pages 100–105, January 2011
How to Cite
Andersson, M., Zetterberg, H., Minthon, L., Blennow, K. and Londos, E. (2011), The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Geriat. Psychiatry, 26: 100–105. doi: 10.1002/gps.2496
- Issue published online: 14 APR 2010
- Article first published online: 14 APR 2010
- Manuscript Accepted: 14 JAN 2010
- Manuscript Received: 18 NOV 2009
- Lewy body disease;
- CSF biomarkers;
- Alzheimer's disease
Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) may be viewed as different points on a continuum reflecting the regional burden and distribution of pathology. An important clinical consideration is overlapping Alzheimer's disease (AD) pathology, since it has been reported that associated AD pathology in DLB shortens survival and leads to a more rapid cognitive decline. We aimed to investigate cerebrospinal fluid (CSF) biomarkers and the associated cognitive profile in DLB and PDD.
Clinically diagnosed DLB (n = 47) and PDD (n = 17) patients from a clinical follow-up programme were investigated. All performed mini mental state examination (MMSE) and went through lumbar puncture at baseline. CSF concentrations of total τ (T-τ), τ phosphorylated at threonine 181 (P-τ181) and the 42 amino acid isoform of amyloid β, Aβ42 were determined.
We found significant differences in T-τ and Aβ42, with a higher level of T-τ and a lower level of Aβ42 in DLB compared to PDD. The combination of T-τ with Aβ42 showed better discrimination between DLB and PDD than either of the measures alone. In DLB, a CSF profile more like the one seen in AD was significantly correlated with worse performance on the orientation and memory of the MMSE.
The correlation suggests a possible link between a higher degree of AD pathology and a profile of more temporal disabilities on cognitive tests in DLB. This might aid in identifying a subgroup of patients with a greater burden of AD pathology in a clinical setting and could have important implications for prognosis. Copyright © 2010 John Wiley & Sons, Ltd.